许文莉,孙金豹

子宫腺肌病是临床上常见的子宫良性病变，主要症状为经量过多、经期延长、子宫增大、痛经及生育能力低下。随着诊断技术的提升以及女性初次生育年龄的推迟，子宫腺肌病患者生育相关的问题逐渐成为临床关注的焦点，本文就子宫腺肌病及其导致的不孕相关问题进行综述。

子宫腺肌病；不孕；发病机制；妊娠结局；治疗

[1] Bergeron C,Amant F.,Ferenczy A.The pathology and physiopathology of adenomyosis.Best Pract.Res.Clin.Obstet.Gynecol.2006;20:511–521. [2] Baboo KD,Chen Z,Zhang X.Progress on medical treatment in the management of adenomyosis.Zhejiang Da Xue Xue Bao Yi Xue Ban.2019 Apr 25;48(2):142-147. [3] Vannuccini S,Petraglia F.Recent advances in understanding and managing adenomyosis.F1000Research.2019;8:283. [4] Vannuccini S,Tosti C,Carmona F,et al.:Pathogenesis of adenomyosis:an update on molecular mechanisms.Reprod Biomed Online.2017;35(5):592–601. [5] Carrarelli P,Yen CF,Arcuri F,et al.:Myostatin,follistatin and activin type II receptors are highly expressed in adenomyosis.Fertil Steril.2015;104(3):744–752. [6] Carrarelli P,Yen CF,Funghi L,et al.:Expression of Inflammatory and Neurogenic Mediators in Adenomyosis.Reprod Sci.2016;24(3):369–375. [7] Aleksandrovych V.,Basta P.,Gil K.Current facts constituting an understanding of the nature of adenomyosis.Adv.Clin.Exp.Med.2019;28:839–846. [8] Guo S.W.The pathogenesis of adenomyosis vis-à-vis endometriosis.J.Clin.Med.2020;9:845–863. [9] Kitawaki J.,Noguchi T.,Amatsu T.,Maeda K.,Tsukamoto K.,Yamamoto T.,Fushiki S.,Osawa Y.,Honjo H.Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.Biol.Reprod.1997;57:514–519. [10] Kitawaki J.,Koshiba H.,Ishihara H.,Kusuki I.,Tsukamoto K.,Honju H.Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.J.Clin.Endocrinol.Metab.2000;85:3292–3296. [11] Shaked S.,Jaffa A.J.,Grisaru D.,Elad D.Uterine peristalsis-induced stresses with the uterine wall may sprout adenomyosis.Biomed.Model.Mechano-Biol.2015;14:437–444. [12] Khan KN,Fujishita A,Mori T.Pathogenesis of Human Adenomyosis:Current Understanding and Its Association with Infertility.J Clin Med.2022 Jul 13;11(14):4057. [13] Spencer T.E.,Hayashi K.,Hu J.,Carpenter K.D.Comparative developmental biology of the mammalian uterus.Curr.Top.Dev.Biol.2005;68:85–122. [14] Ferenczy A.Pathophysiology of adenomyosis.Hum.Reprod.Updat.1998;4:312–322. [15] Zhai J.,Vannuccini S.,Petraglia F.,Giudice L.C.Adenomyosis:Mechanisms and Pathogenesis.Semin.Reprod.Med.2020;38:129–143. [16] Carrarelli P,Yen CF,Funghi L,Arcuri F,Tosti C,Bifulco G,Luddi A,Lee CL,Petraglia F.Expression of Inflammatory and Neurogenic Mediators in Adenomyosis.Reprod Sci.2017 Mar;24(3):369-375. [17] Puente JM,Fabris A,Patel J,et al.:Adenomyosis in infertile women:prevalence and the role of 3D ultrasound as a marker of severity of the disease.Reprod Biol Endocrinol.2016;14(1):60. [18] Mehasseb M.K.,Bell S.C,Pringle J.H,Habiba M.A.:Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium.Fertil.Steril.2010;93:2130-2136. [19] Recent advances in understanding and managing adenomyosis.Vannuccini S,Petraglia F.F1000Res.2019;8:0. [20] Adenomyosis and infertility-review of medical and surgical approaches.Szubert M,Koziróg E,Olszak O,Krygier-Kurz K,Kazmierczak J,Wilczynski J.Int J Environ Res Public Health.2021;18:1235. [21] Xiao Y,Li T,Xia E,Yang X,Sun X,Zhou Y.Expression of integrinβ3 and osteopontin in the eutopic endometrium of adenomyosis during the implantation window.Eur J Obstet Gynecol Reprod Biol 2013;170(02):419–422. [22] Vercellini P.,Consonni D.,Dridi D.,Bracco B.,Frattaruolo M.P.,Somigliana E.Uterine adenomyosis and in vitro fertilization outcome:A systematic review and meta-analysis.Hum.Reprod.2014;29:964–977. [23] Juang CM,Chou P,Yen MS,et al.:Adenomyosis and risk of preterm delivery.BJOG.2007;114(2):165–169. [24] Mochimaru A,Aoki S,Oba MS,Kurasawa K,Takahashi T,Hirahara F.Adverse pregnancy outcomes associated with adenomyosis with uterine enlargement.J Obstet Gynaecol Res.2015 Apr;41(4):529-533. [25] Hashimoto A,Iriyama T,Sayama S,et al.:Adenomyosis and adverse perinatal outcomes:increased risk of second trimester miscarriage,preeclampsia,and placental malposition.J Matern Fetal Neonatal Med.2018;31(3):364–369. [26] Tamura H,Kishi H,Kitade M,et al.:Complications and outcomes of pregnant women with adenomyosis in Japan.Reprod Med Biol.2017;16(4):330–336. [27] Yamaguchi A,Kyozuka H,Fujimori K,Hosoya M,Yasumura S,Yokoyama T,Sato A,Hashimoto K;Japan Environment and Children's Study Group.Risk of preterm birth,low birthweight and small-for-gestational-age infants in pregnancies with adenomyosis:A cohort study of the Japan Environment and Children's Study.Acta Obstet Gynecol Scand.2019 Mar;98(3):359-364. [28] Cozzolino M,Tartaglia S,Pellegrini L,Troiano G,Rizzo G,Petraglia F.The Effect of Uterine Adenomyosis on IVF Outcomes:a Systematic Review and Meta-analysis.Reprod Sci.2022 Nov;29(11):3177-3193. [29] Benaglia L.,Cardellicchio L.,Leonardi M.,Faulisi S.,Vercellini P.,Paffoni A.,Somigliana E.,Fedele L.Asymptomatic adenomyosis and embryo implantation in IVF cycles.Reprod.Biomed.Online.2014;29:606–611. [30] Dueholm M.,Aagaard J.Adenomyosis and IVF/ICSI treatment:Clinical considerations and recommendations.Expert Rev.Endocrinol.Metab.2018;13:177–179. [31] ontis A,D'Alterio MN,Pirarba S,de Angelis C,Tinelli R,Angioni S.Adenomyosis:a systematic review of medical treatment.Gynecol Endocrinol.2016;32:696–700. [32] Niu Z,Chen Q,Sun Y,Feng Y.Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis.Gynecol Endocrinol.2013;29:1026–1030. [33] Rocha TP,et al.Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility:A Systematic Review of Current Options.Reprod Sci.2018;25(4):480–486. [34] Wang PH,Fuh JL,Chao HT,Liu WM,Cheng MH,Chao KC.Is the surgical approach beneficial to subfertile women with symptomatic extensive adenomyosis?J Obstet Gynaecol Res.2009;35:495–502. [35] Li F,Chen J,Yin L,Zeng D,Wang L,Tao H,Wu X,Wei F,Xu F,Shi Q,Lin Z,Wang Z.HIFU as an alternative modality for patients with uterine fibroids who require fertility-sparing treatment.Int J Hyperthermia.

点击下载PDF